TSHA - Taysha Gene Therapies, Inc. Common Stock

Day	1m	10m	60m	PreMarket	Market	AfterHours	Gap
5.18 0.15 (2.9%)	---	0.0 (0.0%)	0.0 (0.01%)	0.13 (2.51%)	0.0 (0.0%)	-0.02 (-0.33%)	-0.02 (-0.33%)

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.

Category: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

Market Period: Closed

Earnings & Ratios

Basic EPS:: -0.09
Diluted EPS:: -0.09
Basic P/E:: -59.2222
Diluted P/E:: -59.2222
RSI(14) 1m:: 100.0
VWAP:: 5.33
RVol:: 0.3574

Events

Period	Kind	Movement	Occurred At
1m	Price decrease 1m	5.39 -0.1 (-1.73%)	Oct 15 09:37
1m	Price increase 1m	5.49 +0.08 (+1.48%)	Oct 15 09:35
60m	Price increase 60m	5.49 +0.28 (+5.37%)	Oct 15 09:35
1m	Price increase 1m	5.42 +0.06 (+1.03%)	Oct 15 09:34
1m	Price decrease 1m	5.38 -0.06 (-1.1%)	Oct 15 09:33